Confidential draft– do not distribute

First Page		Document Content
Date: 2014-11-17 22:08:29 Biotechnology Immunosuppressants Autoimmune diseases Immune system Certolizumab pegol Monoclonal antibodies Rheumatoid arthritis TNF inhibitor Tumor necrosis factor-alpha Medicine Anatomy Biology		Confidential draft– do not distribute Add to Reading List Source URL: www.astellas.com Download Document from Source Website File Size: 45,48 KB Share Document on Facebook

	UCB Presents Latest Research from Immunology Portfolio at American College of Rheumatology Annual Meeting Data presentations include:  Positive results from Period 1 of the C-EARLY™ Phase 3 study of CIMZIA® (certol DocID: 1rakB - View Document
	JUNE 2015 TABLE OF CONTENTS INTRODUCTION DocID: 1qDC6 - View Document
	TABLE OF CONTENTS INTRODUCTION 2 DocID: 1qs3R - View Document
	TABLE OF CONTENTS INTRODUCTION 2 DocID: 1qius - View Document
	FEBRUARY 2015 TABLE OF CONTENTS INTRODUCTION DocID: 1qcKs - View Document